London & Capital Asset Management Ltd Sells 54,845 Shares of Sanofi $SNY

London & Capital Asset Management Ltd trimmed its position in Sanofi (NASDAQ:SNY) by 67.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,110 shares of the company’s stock after selling 54,845 shares during the period. London & Capital Asset Management Ltd’s holdings in Sanofi were worth $1,232,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in SNY. Brighton Jones LLC boosted its holdings in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after buying an additional 1,869 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after acquiring an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after acquiring an additional 752 shares during the period. Sivia Capital Partners LLC grew its position in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after acquiring an additional 347 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in shares of Sanofi by 233.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $48,000 after purchasing an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Up 0.6%

NASDAQ SNY opened at $48.66 on Monday. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. The stock has a market cap of $118.68 billion, a PE ratio of 13.52, a P/E/G ratio of 1.26 and a beta of 0.45. The stock’s 50 day moving average is $47.54 and its 200 day moving average is $48.58.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Finally, Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Sanofi presently has an average rating of “Hold” and a consensus target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.